Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Daniel Kapp

Plastic Surgery West Palm Beach, FL Medical Doctor

NPI 1235132416 CMS profile 191440

1500 N Dixie Hwy, Ste 304, West Palm Beach, FL 33401

Open in the dashboard

General payments

$252,125

417 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Daniel Kapp of West Palm Beach, FL is reported in the CMS Open Payments database as having received $252,125 across 417 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Plastic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $79,439 79
2024 General $62,423 67
2023 General $28,097 65
2022 General $43,306 71
2021 General $17,550 53
2020 General $4,760 30
2019 General $16,551 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Daniel Kapp
  • Plastic Surgery median
  • Middle half of Plastic Surgery
  • National median

In program year 2025, general payments to Daniel Kapp were reported at $79,439. Among 3,701 Plastic Surgery profiles paid that year, the median was $379 and the middle half received between $138 and $1,100.

Show as a table
Year Daniel Kapp Plastic Surgery median Middle half National median
2019 $16,551 $371 $122–$1,483 $163
2020 $4,760 $158 $52–$438 $114
2021 $17,550 $249 $87–$752 $132
2022 $43,306 $274 $102–$793 $149
2023 $28,097 $299 $113–$891 $160
2024 $62,423 $361 $124–$1,062 $164
2025 $79,439 $379 $138–$1,100 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organogenesis Inc. $221,178 166 payments
  2. TELA Bio, Inc. $16,594 89 payments
  3. Allergan Inc. $5,028 7 payments
  4. Davol Inc. $2,962 2 payments
  5. Sientra, Inc. $1,133 19 payments
  6. Integra LifeSciences Corporation $655 22 payments
  7. Royal Biologics $610 2 payments
  8. Mentor Worldwide LLC $556 14 payments
  9. Smith+Nephew, Inc. $514 14 payments
  10. Medline Industries, Inc. $513 19 payments
  11. Other $2,383 63 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $129,588 23 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $85,426 41 payments
  3. Travel and Lodging $17,466 47 payments
  4. Food and Beverage $13,395 304 payments
  5. Honoraria $6,250 2 payments
Products named General payments · program years 2019–2025
  1. Affinity $94,487 37 payments
  2. NuShield $87,715 25 payments
  3. PURAPLY WOUND MATRIX $79,181 33 payments
  4. APLIGRAF Wound Care $73,198 26 payments
  5. NOVACHOR $67,353 20 payments
  6. Puraply $46,853 56 payments
  7. Apligraf Wound Care $22,444 8 payments
  8. Puraply Antimicrobial $19,484 10 payments
  9. CYGNUS DUAL $17,897 3 payments
  10. OviTex Reinforced Bioscaffold With Permanent Polymer (OviTex) $15,054 67 payments
  11. Other $55,892 297 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 9 drugs

Part D claims

206

Median for Plastic and Reconstructive Surgery: 61

Drug cost

$7,960

Median for Plastic and Reconstructive Surgery: $369

Branded share of claims

18.9%

Median for Plastic and Reconstructive Surgery: 30%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Santyl Collagenase Clostridium Hist. Brand 13 $6,527
Doxycycline Hyclate Generic 57 $509
Cefadroxil Generic 50 $360
Cyclobenzaprine Hcl Generic 17 $119
Ciprofloxacin Hcl Generic 13 $115
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 15 $89
Mupirocin Generic 12 $87
Amoxicillin-Clavulanate Potass Amoxicillin/Potassium Clav Brand 11 $85
Ondansetron Hcl Generic 18 $68

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,638 Part D prescribers listed as Plastic and Reconstructive Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 85 billing codes

Paid by Medicare

$667,722

Of which drugs: $370,808

Medicare patients

313

Average age 81

Services billed

2,462

166 women, 147 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 60%
Ischemic heart disease 41%
Atrial fibrillation 30%
Chronic kidney disease 28%
Osteoporosis 27%
Diabetes 26%
Heart failure 26%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Cygnus dual, per square centimeter Q4282 Office 12 360 $251,541

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

417 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic Surgery in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record